APSR2026-506

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-013
P90
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220728-46904-Early IPF biomarker A0 APSR Penang 20261119.docx_433902.pdf
Format: PDF Only
16. Interstitial Lung Disease
14

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Masaki Okamoto * NHO Kyushu Medical Center Department of Respirology Fukuoka Japan
Toyoshi Yanagihara - Fukuoka University Hospital Department of Respiratory Medicine Fukuoka Japan
Kosaku Komiya - Oita University Faculty of Medicine Respiratory Medicine and Infectious Diseases Oita Japan
Yoshiaki Zaizen - Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine Kurume Japan
Kazunori Tobino - Iizuka Hospital Department of Respiratory Medicine Iizuka Japan
Hidenori Ichiyasu - Kumamoto University Hospital Department of Respiratory Medicine Kumamoto Japan
Kazuya Ichikado - Saiseikai Kumamoto Hospital Division of Respiratory Medicine Kumamoto Japan
Hiroshi Ishii - Fukuoka University Chikushi Hospital Department of Respiratory Medicine Fukuoka Japan
Naoki Hamada - Fukuoka University Hospital Department of Respiratory Medicine Fukuoka Japan
Norikazu Matsuo - NHO Kyushu Medical Center Department of Respirology Fukuoka Japan
Takashi Nouno - NHO Kyushu Medical Center Department of Respirology Fukuoka Japan
Noriho Sakamoto - Nagasaki University Graduate School of Biomedical Sciences Department of Respiratory Medicine Nagasaki Japan
Hiroshi Mukae - Nagasaki University Graduate School of Biomedical Sciences Department of Respiratory Medicine Nagasaki Japan
Tomoaki Hoshino - Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine Kurume Japan
 
Presenting Author Details
Masaki
Okamoto
okamoto_masaki@med.kurume-u.ac.jp
+81928520700
51-60
Japan
Original Research
A Novel Serum Biomarker Signature including IL-10, IL-18, and SP-D Predicts Acute Exacerbation in Early-Stage Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study
Maximum 25 words
Abstract Content
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a fatal complication that can occur even in early-stage patients. While early intervention with antifibrotic drugs is recommended, reliable "decision-making markers" to identify high-risk patients in the early stages remain unestablished.
We analyzed blood samples obtained from 192 patients with early-stage IPF (Japanese severity stage I/II) who participated in the multicenter, prospective, observational cohort study (Kyushu and Okinawa study). Blood levels of 46 proteins were quantified using multiplex immunoassay systems. Independent predictors for AE-IPF (within 3 years) were identified via multivariable forward stepwise logistic regression. A biomarker-based risk score was developed and validated using ROC analysis and hierarchical cluster analysis (HCA).
Twenty-five patients (13.0%) developed AE-IPF during the observation period. Multivariable analysis identified IL-10 (OR 2.029, p=0.022), IL-18 (OR 2.880, p=0.029), and SP-D (OR 1.782, p=0.043) as independent risk factors. HCA stratified patients into two distinct clusters; the "High-risk signature" group (Cluster 2) exhibited a significantly higher incidence of AE-IPF (24.3% vs. 6.7%, p<0.01) and shorter overall survival (p=0.026). The integrated model combining these biomarkers with clinical factors (GAP stage, desaturation during 6MWT, and CT-UIP pattern) achieved an AUC of 0.792 for predicting AE-IPF.
The combined signature of IL-10, IL-18, and SP-D is strong predictor of AE-IPF and mortality in early-stage patients. This simple blood-based tool may facilitate personalized decision-making for initiating early antifibrotic therapy to improve patient outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
biomarker, idiopathic interstitial pneumonia, acute exacerbation, interleukin-18, interleukin-10, surfactant protein-D
maximum 3 keywords and no abbreviations, separated by commas
Masaki Okamoto, Toyoshi Yanagihara, and Tomoaki Hoshino: received a research grant from Boehringer Ingelheim outside the scope of this work.; Masaki Okamoto received lecture fees from Nippon Boehringer-Ingelheim, Co., Ltd.; Yoshiaki Zaizen received consultation fees from Artenix BV and lecture fees from Nippon Boehringer-Ingelheim, Co.; Ltd. Other authors have no conflict of interest. ・The author(s) meet criteria for authorship as recommended by the ICMJE. ・This was an independent, investigator-initiated study supported by Boehringer Ingelheim. ・Boehringer Ingelheim had no role in the design, analysis or interpretation of the results in   this study; Boehringer Ingelheim was given the opportunity to review the manuscript for   medical and scientific accuracy as it relates to Boehringer Ingelheim substances, as well as   intellectual property considerations.
245